Renal Artery Denervation In Addition to Catheter Ablation To Eliminate Atrial Fibrillation
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 302 participants.
Also called NCT01873352
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 302 participants
- Registry
-
NCT01873352
-
- Other papers using this trial's data
- Effect of Renal Denervation and Catheter Ablation vs Catheter Ablation Alone on Atrial Fibrillation Recurrence Among Patients With Paroxysmal Atrial Fibrillation and Hypertension: The ERADICATE-AF Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Russia
- Registry status
- Completed
Technical summary
Registry record NCT01873352. Randomized; single masking; primary purpose treatment. Start 2013-06-20 (actual); primary completion 2019-03-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Renal Artery Denervation In Addition to Catheter Ablation To Eliminate Atrial Fibrillation
- Acronym
- ERADICATE--AF
- Condition
- Atrial Fibrillation
- Condition
- Hypertension
- Intervention (Procedure)
- catheter ablation
- Intervention (Procedure)
- renal sympathetic denervation
- Lead sponsor
- Meshalkin Research Institute of Pathology of Circulation
Record details
- Record id
cardio:ct-nct01873352- Content hash
f9daec46891a46279500d2e4c62ed33b577968723a6cf8d5a884c2eac9c17f91